Inside the Personalized Medicine Toolbox: GCxGC-Mass Spectrometry for High-Throughput Profiling... - - Chromatography Online
FindAnalytichem Custom Search
About Search
Inside the Personalized Medicine Toolbox: GCxGC-Mass Spectrometry for High-Throughput Profiling...

Inside the Personalized Medicine Toolbox: GCxGC-Mass Spectrometry for High-Throughput Profiling of the Human Plasma Metabolome

Personalized medicine advocates have been frustrated by the issue of analyte component resolution in biomolecular profiling. Because complex human biological samples such as plasma, serum, or urine contain ~103–107 unique molecular entities, the analyte capacity of any high-throughput platform is typically exceeded. In our attempt to overcome this problem, we employed the use of comprehensive two-dimensional gas chromatography (GC×GC) combined with time-of-flight mass spectrometry (TOF-MS) for high-throughput profiling of the human plasma metabolome. The profiling experiments demonstrated the capability of a GC×GC-TOF-MS approach with regard to component resolution as well as overall utility for comparative metabolomic analyses employing plasma samples from a "control" cohort (81 samples) versus a cardiovascular-compromised cohort (15 samples) of individuals. The use of the GC×GC separation has resulted in a platform that provides more than an order of magnitude greater resolving power while at the same time not affecting the overall experimental run time. Additionally, the high-throughput approach provides information-rich datasets that can be used to distinguish the control and disease sample cohorts. Such results suggest that high-throughput, high-coverage profiling capabilities, such as those afforded by GC×GC-TOF-MS techniques, can impact the development of personalized medicine in which future disease prevention, diagnosis, and treatment are tailored to an individual's unique molecular makeup. Challenges to full implementation of high-throughput metabolite profiling by GC×GC-TOF-MS as well as future directions are discussed.


Figure 1
There is widespread medical, scientific, and general public interest in the rapidly emerging field of personalized medicine (1). The Personalized Medicine Coalition has defined one aspect of personalized medicine as the ability to manage disease (and disease predisposition) based upon biomolecular analysis (2). As such, molecular classifications at the genome, transcriptome, proteome, and/or metabolome levels has taken on ever more importance(2,3). This new paradigm in healthcare has lead to a race for the identification of efficacious biomarkers, panels of biomarkers or profiles that can be used for preventative, predictive, diagnosis, and prognosis of disease as well as assessment of overall general health and wellness (1). In part, the development of personalized medicine has been enabled due to the advent of new analytical and computational tools not available previously. One can envision that the new tools will provide important information to the individual patient or consumer permitting them to make informed decisions regarding their general health and well being as well as their ability to manage disease issues more efficiently. This is captured schematically in Figure 1.

Despite the technological developments of the past decade, the expectation of personalized medicine based upon individual molecular analyses has been tempered somewhat, due in part to the tremendous analytical challenge presented by the complexity of human biological samples such as plasma, sera, or urine. For example, it has been estimated that the human metabolome contains ~2000–2500 unique molecular analytes (4–6). This is considerably lower in number than the estimated human proteome (7), but nonetheless presents a considerable analytical challenge. In addition, there is greater disparity in the physicochemical properties of the metabolome constituents (8,9). This creates a considerable challenge in terms of utilization of a single analytical technique to profile the human metabolome (10). Another problem is the presence of incomplete or limited databases as well as the lack of standardization across databases. Thus, the ability to identify metabolite components based upon database searches is hindered. A final problem is that the degree of variability in concentrations for many metabolites among different individuals is largely unknown. Such problems are not so unlike those encountered in proteomics efforts and as such require a similar solution: high-throughput analyses to determine metabolome variability for a large number of components. However, it has been argued that a comprehensive understanding of the metabolome would help to discover biomarkers associated with disease as it (metabolomics) "will more precisely take into account the effects of lifestyle, diet, and the environment" (5).

Having noted the difficulties in characterizing the metabolome, it is important to consider the current analytical methods for individual sample profiling. The most widely used techniques include 1H nuclear magnetic resonance (NMR) spectroscopy, direct infusion mass spectrometry (MS), Fourier transform-infrared (FT-IR) spectroscopy, and liquid chromatography (LC) and gas chromatography (GC) coupled with MS (10,11). Each of these techniques has its advantages as well as its limitations and for this reason, metabolomic profiling often requires the use of multiple approaches (10,12–17). The relatively recent technique of comprehensive two-dimensional (2D) GC (GC×GC) (18–23) is gaining acceptance as a powerful tool for the rapid profiling of complex biological samples (24,25). In addition to the increased peak capacity, the advantage of the approach is that the extra separation dimension reduces the congestion of eluted peaks, thereby allowing the resolution of lower signal species (24).

The work reported here presents an evaluation of a GC×GC-TOF-MS analytical approach for human plasma metabolite profiling. A total of 96 plasma samples have been analyzed using a rapid throughput approach requiring approximately 20 min (the separation time is ~20 min and the cycle time is ~30 min; see the following) per sample. The analytical platform is evaluated based upon robustness, resolving power, and metabolome coverage, and to some degree, the quality of the data. We present a comparative metabolomics study in which the plasma metabolite profiles of 81 control cohort samples are compared to those from a cardiovascular-compromised patient sample cohort (15 total). The limitations of the approach as they pertain to profiling efficacy and personalized medicine as well as future directions for the technique are discussed in the following.


ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All Comments submitted are subject to review, and may be delayed before posting. Comments will be posted at the discretion of the editor.
LCGC E-mail Newsletters
Select each newsletter you wish to subscribe for:
| Monthly
| Weekly
| Monthly
 Name:
 E-mail:
more info
Survey
Are you aware of CHROMacademys e-learning modules?
Yes and would like to know more
Yes but not interested
No but interested in learning more
No not interested
Yes and would like to know more
56%
Yes but not interested
11%
No but interested in learning more
33%
No not interested
0%
View Results
Source: LCGC North America,
Click here